Libido Pill’s Risks Have Insurers Weighing Whether to Pay

Updated on

Meet Addyi, the FDA-Approved Women's Sex-Drive Pill

Health insurers are grappling with the question of whether to cover the new pink pill to treat low libido in women, which will hit U.S. pharmacy shelves this year with a prominent warning label for serious side effects such as fainting.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.